Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery?
The aim of this study was to compare 6% hydroxyethyl starch 130/0.4 with 4% succinylated gelatin for priming the cardiopulmonary bypass circuit and as volume replacement in patients undergoing coronary artery bypass, in terms of postoperative bleeding, blood transfusion requirements, renal function, and outcome after surgery. Forty-five patients received 6% hydroxyethyl starch 130/0.4 (Voluven) and another 45 were given 4% succinylated gelatin (Gelofusine) as the priming solution for the cardiopulmonary bypass circuit as well as for volume replacement. Postoperative bleeding was quantified from the hourly chest drainage in the first 4 h and at 24 h postoperatively. The baseline characteristics of both groups were similar. In the hydroxyethyl starch group, the total amount of colloid used was 1.9 +/- 1.0 L, while the gelatin group had 2.0 +/- 0.7 L. There was no significant difference in hourly chest drainage between groups. Blood transfusion requirements, estimated glomerular filtration rate, extubation time, intensive care unit and hospital stay were similar in both groups. It was concluded that 6% hydroxyethyl starch 130/0.4 is a safe alternative colloid for priming the cardiopulmonary bypass circuit and volume replacement in patients undergoing coronary artery bypass surgery.
Ooi
Joanna Su Min
JS
Division of Cardiothoracic Anaesthesia, Department of Anaesthesiology & Intensive Care, Faculty of Medicine, Heart and Lung Centre, Hospital Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia. joanna@ppukm.ukm.my
Ramzisham
Abdul Rahman Mohd
AR
Zamrin
Mohd Dimon
MD
D000368:Aged; D001803:Blood Transfusion; D002315:Cardiopulmonary Bypass / Q000009:adverse effects* / Q000379:methods; D015505:Chest Tubes; D001026:Coronary Artery Bypass; D003422:Critical Care; D004322:Drainage / Q000295:instrumentation; D005260:Female; D005780:Gelatin / Q000009:adverse effects*; D005919:Glomerular Filtration Rate; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010952:Plasma Substitutes / Q000009:adverse effects*; D011097:Polygeline / Q000009:adverse effects*; D019106:Postoperative Hemorrhage / Q000209:etiology / Q000517:prevention & control; D011446:Prospective Studies; D051437:Renal Insufficiency / Q000209:etiology / Q000503:physiopathology; D018570:Risk Assessment; D016037:Single-Blind Method; D013386:Succinates / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
C485123:HES 130-0.4; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D013386:Succinates; C060085:succinylated gelatin; D005780:Gelatin; D011097:Polygeline